LINC00313 functions as an oncogenic propellant and immunosuppressive marker in lung adenocarcinoma

Despite advances in treatments, the prognosis for lung adenocarcinoma (LUAD) remains poor, underscoring the urgent need to identify novel therapeutic strategies. This study was conducted to investigate the potential role of LINC00313 as a biomarker and therapeutic target for LUAD. Databases GEPIA2 and GEO were used to analyze LINC00313 expression and prognosis. Analyses of pathways associated with LINC00313, and its relationships with immune infiltration, checkpoint therapy response and drug response were conducted using different bioinformatics tools. siRNA transfection, qRT-PCR, transwell and colony formation assays were performed on LUAD cells (A549). LINC00313 is significantly upregulated in LUAD, and its expression is associated with high-grade cancer, poor prognosis and metastasis. <i>In vitro</i> studies showed that silencing LINC00313 reduced LUAD cell migration, invasion, and colony formation. Bioinformatics analyses indicated that LINC00313 expression was negatively associated with immune cell infiltration and the efficacy of immune checkpoint inhibitor therapy. Sensitivity analysis of chemotherapeutic drugs found that high expression of LINC00313 attenuated the effect of chemotherapeutic drugs like cisplatin, dabrafenib and lapatinib on LUAD. In conclusion, LINC00313 holds potential as a valuable biomarker and therapeutic target for the treatment of LUAD. However, further research is warranted to fully elucidate its clinical applications. Lung adenocarcinoma (LUAD) is the most common type of lung cancer, but survival rates remain low despite many available treatments. This study investigated a molecule called LINC00313 to see if it could be used as a marker or target for treating LUAD. We used databases like GEPIA2 and GEO to look at how much LINC00313 is present in LUAD tissues compared to normal lung tissues. We also used computer tools to study how LINC00313 might affect cancer cell behavior, immune responses, and drug effectiveness. In the lab, we tested how silencing LINC00313 affected the growth and spread of LUAD cells. Our results showed that LINC00313 is much higher in LUAD tissues than in normal tissues. High levels of LINC00313 were linked to more aggressive cancer, worse outcomes, and spread to other parts of the body. When we turned off LINC00313 in the lab, the cancer cells were less able to move, invade, and form colonies. Our analysis also suggested that LINC00313 affects cell adhesion and immune signals, and it seems to make LUAD cells less responsive to certain chemotherapy drugs. Overall, LINC00313 could be a useful marker or target for treating LUAD, but more research is needed to fully understand how it can be used in the clinic. LINC00313 is significantly overexpressed in LUAD tissues compared to normal tissues, correlating strongly with high-grade cancer, poor patient prognosis, and metastasis.Silencing of LINC00313 in LUAD cells significantly reduces cell migration, invasion, and colony formation <i>in vitro</i>.Bioinformatics analyses link LINC00313 overexpression to dysregulation of cell adhesion-related signals and immune-related signaling pathways, potentially driving tumor progression.High LINC00313 expression is associated with reduced immune cell infiltration, poorer response to immune checkpoint inhibitor therapy, and attenuated efficacy of chemotherapeutic drugs.These findings strongly support LINC00313 as a promising biomarker for prognosis and a potential therapeutic target for LUAD. LINC00313 is significantly overexpressed in LUAD tissues compared to normal tissues, correlating strongly with high-grade cancer, poor patient prognosis, and metastasis. Silencing of LINC00313 in LUAD cells significantly reduces cell migration, invasion, and colony formation <i>in vitro</i>. Bioinformatics analyses link LINC00313 overexpression to dysregulation of cell adhesion-related signals and immune-related signaling pathways, potentially driving tumor progression. High LINC00313 expression is associated with reduced immune cell infiltration, poorer response to immune checkpoint inhibitor therapy, and attenuated efficacy of chemotherapeutic drugs. These findings strongly support LINC00313 as a promising biomarker for prognosis and a potential therapeutic target for LUAD.